• MANE is trading 4.2% down today at $121.52 as investors lock in gains following a 38% rally over the past week.
  • The recent surge was primarily driven by positive topline results from Veradermics' Phase 2/3 '302' study of VDPHL01 for pattern hair loss, announced in April and May.
  • Today's decline appears to be a technical correction and profit-taking after this significant outperformance, rather than a reaction to new negative headlines.